Literature DB >> 15279759

New Treatments in Pediatric Brain Tumors.

Roger J. Packer1, Alyssa Reddy.   

Abstract

The management of childhood brain tumors is likely to change dramatically during the next few years. Current treatment has improved outcome in some types of brain tumors, but for most patients, survival rates have not changed during the past two decades. Advances in surgery, radiation therapy, and chemotherapy are likely to marginally increase survival, and possibly improve the quality of life for long-term survivors. As the molecular factors underlying childhood brain tumors are better elucidated, molecular-targeted therapy will become a major modality of treatment with the promise of not only increasing the likelihood of survival, but also decreasing treatment-related sequelae.

Entities:  

Year:  2004        PMID: 15279759     DOI: 10.1007/s11940-996-0029-3

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  31 in total

1.  Chemotherapy response rates in recurrent/progressive pediatric glioma; results of a systematic review.

Authors:  M Huncharek; L Wheeler; R McGarry; J F Geschwind
Journal:  Anticancer Res       Date:  1999 Jul-Aug       Impact factor: 2.480

2.  Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis.

Authors:  S L Palmer; O Goloubeva; W E Reddick; J O Glass; A Gajjar; L Kun; T E Merchant; R K Mulhern
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

3.  Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study.

Authors:  M D Ris; R Packer; J Goldwein; D Jones-Wallace; J M Boyett
Journal:  J Clin Oncol       Date:  2001-08-01       Impact factor: 44.544

4.  Stereotactic radiosurgery for recurrent ependymoma.

Authors:  S L Stafford; B E Pollock; R L Foote; D A Gorman; D F Nelson; P J Schomberg
Journal:  Cancer       Date:  2000-02-15       Impact factor: 6.860

5.  Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.

Authors:  J M Markert; M D Medlock; S D Rabkin; G Y Gillespie; T Todo; W D Hunter; C A Palmer; F Feigenbaum; C Tornatore; F Tufaro; R L Martuza
Journal:  Gene Ther       Date:  2000-05       Impact factor: 5.250

6.  Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study.

Authors:  P M Zeltzer; J M Boyett; J L Finlay; A L Albright; L B Rorke; J M Milstein; J C Allen; K R Stevens; P Stanley; H Li; J H Wisoff; J R Geyer; P McGuire-Cullen; J A Stehbens; S B Shurin; R J Packer
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

7.  Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas.

Authors:  R J Packer; J Ater; J Allen; P Phillips; R Geyer; H S Nicholson; R Jakacki; E Kurczynski; M Needle; J Finlay; G Reaman; J M Boyett
Journal:  J Neurosurg       Date:  1997-05       Impact factor: 5.115

8.  Atypical teratoid/rhabdoid tumor of the central nervous system: report on workshop.

Authors:  Roger J Packer; Jaclyn A Biegel; Susan Blaney; Jonathan Finlay; J Russell Geyer; Richard Heideman; Joanne Hilden; Anna J Janss; Larry Kun; Gilbert Vezina; Lucy B Rorke; Malcolm Smith
Journal:  J Pediatr Hematol Oncol       Date:  2002 Jun-Jul       Impact factor: 1.289

9.  Stereotactic radiosurgery for pilocytic astrocytomas when multimodal therapy is necessary.

Authors:  Constantinos G Hadjipanayis; Douglas Kondziolka; Paul Gardner; Ajay Niranjan; Shekhar Dagam; John C Flickinger; L Dade Lunsford
Journal:  J Neurosurg       Date:  2002-07       Impact factor: 5.115

10.  Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945.

Authors:  J H Wisoff; J M Boyett; M S Berger; C Brant; H Li; A J Yates; P McGuire-Cullen; P A Turski; L N Sutton; J C Allen; R J Packer; J L Finlay
Journal:  J Neurosurg       Date:  1998-07       Impact factor: 5.115

View more
  1 in total

1.  OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas.

Authors:  David C Adamson; Qun Shi; Matthew Wortham; Paul A Northcott; Chunhui Di; Christopher G Duncan; Jianjun Li; Roger E McLendon; Darell D Bigner; Michael D Taylor; Hai Yan
Journal:  Cancer Res       Date:  2009-12-22       Impact factor: 12.701

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.